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Abstract
Objectives: To determine how many women participate in all three recommended cancer screening programmes (breast,
cervical, and bowel). During their early 60s, English women receive an invitation from all the three programmes.
Methods: For 3060 women aged 60–65 included in an England-wide breast screening case–control study, we investigated the
number of screening programmes they participated in during the last invitation round. Additionally, using the Fingertips data-
base curated by Public Health England, we explored area-level correlations between participation in the three cancer screening
programmes and various population characteristics for all 7014 English general practices with complete data.
Results: Of the 3060 women, 1086 (35%) participated in all three programmes, 1142 (37%) in two, 526 (17%) in one, and 306
(10%) in none. Participation in all three did not appear to be a random event (p< 0.001). General practices from areas with less
deprivation, with more patients who are carers or have chronic illnesses themselves, and with more patients satisfied with the
provided service were significantly more likely to attain high coverage rates in all programmes.
Conclusions: Only a minority of English women is concurrently protected through all recommended cancer screening
programmes. Future studies should consider why most women participate in some but not all recommended screening.
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Introduction
About 50% of British men and 40% of women born in
1950 or later will develop (any) cancer during their life,1
and about half will die within 10 years after the diagnosis.2
Life-saving screening for cervical, breast, and bowel cancer
is currently offered in many developed countries. While
cytological screening prevents substantially more than
half of all deaths due to cervical cancer,3 mammography
prevents about 25% of deaths due to breast cancer among
those who are invited to screening.4 Faecal occult blood
testing can prevent about 15% of deaths due to bowel
cancer, although other methods such as flexible sigmoid-
oscopy can potentially prevent even more.5,6 Women tend
to be invited for screening for multiple cancers concurrent-
ly throughout a large part of their adult lives: for cervical
screening every three to five years, for breast screening
every two to three years, and for bowel screening every
two years.7 They may receive as many as six to eight
screening invitations every five years during their 50s and
60s. Most welcome the idea of having cancer screening
available to them, even if they do not invariably take up
the offer.8 This is reflected in relatively high observed
screening participation, although participation varies by
country and cancer type.7,9
Factors associated with non-participation are largely
shared between the three screening programmes.10–15
Generally, non-participants are less likely than partici-
pants to be aware of screening, and are also less likely to
exhibit behaviours consistent with a healthy lifestyle.16–19
Based on these shared patterns, it might be hypothesized
that the three screening programmes must reach roughly
the same women. Multiple studies showing that the
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likelihood of participation in a given screening programme
increases with participation in a different programme
could be considered to support this hypothesis.20–26 In
the case of English women in their 60s, where the lowest
participation is observed for bowel screening (57%),27 this
would mean that close to half of all women should be
simultaneously protected from an early death from all
three cancers. This, however, has not been tested previous-
ly, and doing so is the aim of our study.
Methods
In England, cancer screening is implemented by the
National Health Service (NHS) free of charge. Cervical
screening with cytology started in 1988. The programme
invites women aged 25–64, with women above age 50 rec-
ommended five-yearly screening (younger women are
invited every three years). Mammographic breast screen-
ing also started in 1988, targeting women aged 50–64
(50–70 since 2005) every three years. Bowel screening
with guaiac faecal occult blood testing started in 2006,
although it was not fully rolled out until 2010. It invites
men and women aged 60–69 (60–74 since 2010) every two
years. No other type of cancer screening is currently
offered to the English population. Screening invitations
are sent by each programme separately, and are not
timed to coincide even if several are sent in the same cal-
endar year. Officially reported five-year coverage rates in
cervical screening for women aged 60–64 with a cervix
were 75% in 2010 and 73% in 2011.28 Of all resident
women attaining that age, 21% had had a hysterectomy,29
which means that 58–59% ([75% or 73%] (100%–21%))
of all resident women had been screened. In breast screen-
ing, three-year coverage at age 60–64 was 78% in 2010/
11,30 while bowel screening uptake among women invited
for the first time was estimated to be 57% in 2010 and 59%
in 2011 (coverage rates have not been reported).27
Individual-level data
The individual-level data were from women who served as
controls in a nationwide case–control study on the English
breast screening programme,31 which evaluates the effect
of breast screening on breast cancer mortality. Cases died
from breast cancer aged 47–89 in 2010–2011 (the most
recent data made available for this research) and were
diagnosed at age 47–89 in 1990 or later. Two controls
were matched on age and screening area to each case
(relaxed to a single control if necessary). They were alive
at their matched case’s date of death, and were selected
from among all women registered with the English NHS
since at least age 47. The matched case’s date of death was
the last date on which the controls were known to be alive.
We refer to this as the woman’s reference date, and her
screening participation was determined prior to this date.
National Health Application and Infrastructure Services
at NHS Digital extracted screening records for each
woman from the inception of the three programmes.
Women were “concurrently” screened in the last round
(before the reference date) if they had at least one screen-
ing record from each programme during the recommended
interval plus one year (to account for reasonable delays),
in six years for cervical (ADHE in Figure 1), four years for
breast (BDHF), and three years for bowel screening
(CDHG). Women must have been aged 60–65 at their ref-
erence date. Younger women are not invited for bowel
screening, whereas older women may not have been eligi-
ble for cervical screening in the last six years. For a refer-
ence date in 2010, those who satisfied this age criterion
were born in 1945–1949. For a reference date in 2011,
this was 1946–1950. The youngest women in these cohorts
turned 60 in the calendar year preceding the reference date.
From the 17,993 controls in the complete case–control
study, 3060 (17%) were born in the selected years.
We categorized women according to their concurrent
participation in the last screening round: in all three pro-
grammes, in none, or in any combination of two or a
single programme. We tested the assumption that concur-
rent (non-)participation was randomly distributed by cal-
culating the v2 statistic comparing the observed with the
expected numbers of women who participated in the last
round in all three programmes, or in none. To determine
the expected numbers, we assumed that some women con-
sistently avoid participating in any screening, and divided
the studied population into women who underwent screen-
ing at least once in at least one programme (ever partic-
ipants, NEP) and those who were never screened in any
programme (never participants, NNP) according to screen-
ing records since the inception of the programmes. The
expected number of women concurrently participating in
all three programmes under the assumption of random-
ness was:
NEP  Nbreast=NEPð Þ  Ncervix=NEPð Þ  Nbowel=NEPð Þ
þNNP  0
where Nbreast, Ncervix, and Nbowel denoted women who par-
ticipated in the last round before the reference date in
breast, cervical, and bowel screening, respectively.
Accordingly, the expected number of women not partici-
pating in the last round in any programme was:
NEP  NEP Nbreastð Þ=NEPð Þ  NEP Ncervixð Þ=NEPð Þ
 NEP Nbowelð Þ=NEPð Þ þNNP
For women participating in a given programme, we
reported the proportions who also participated in no,
one, or both other programmes. The same was done for
women not participating in the same programme. We
compared the patterns by calculating relative proportions
(RPs) and calculated the 95% confidence intervals (CIs)
for RPs by assuming that their logarithms were approxi-
mately normally distributed.
We tested the robustness of the results on two aspects.
Firstly, we did not have information on the women’s
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hysterectomy status. The proportion of women without a
cervix increases with age; in 2010–2011, 6% of English
women aged 45–49 and 21% of those aged 60–64 ceased
to be eligible for cervical screening after a hysterectomy.29
Including the same birth cohorts as in the main analysis,
we assessed concurrent screening participation before age
54, i.e. when women were at their youngest to be eligible
for two screening programmes. Here, concurrent partici-
pation was determined as at least one cervical screening
sample in the six-year period (LIKN in Figure 1), com-
bined with at least one breast screening sample in the four-
year period preceding the 54th birthday (MJKN).
Secondly, our data originate from a period when bowel
screening was in the process of being rolled out nationally.
We repeated the main analysis by restricting the studied
sample to 2391 (78%) women with a record of bowel
screening invitation sent in the year preceding their refer-
ence date at the latest. Here, participation in screening was
determined within the same time windows as in the main
analysis (Figure 1: ADHE for cervical, BDHF for breast,
and CDHG for bowel screening).
General practice data
Because no information on the women’s background was
available from the case–control dataset, we used general
practice data from the same source population to
investigate area-level correlations between screening par-
ticipation and various population characteristics. The
Fingertips database curated by Public Health England
reports health-related data for England, aggregated by
administrative area. It was accessed through fingertipsR
package for R version 0.2.0.32 We retrieved the most
recent data (financial year 2017/2018, when all pro-
grammes were rolled out nationally), and selected all
7099 general practices with a known Quality of
Outcomes Framework list size. We excluded 85 (1.2%)
practices with any missing data on practice’s population
characteristics or screening participation, leaving 7014
practices for the analysis. Fingertips aggregates screening
participation by general practice for each programme sep-
arately, and reports it as: the proportion of women aged
50–70 screened for breast cancer in the prior 36months;
the proportion of women aged 25–64 screened for cervical
cancer in prior 3 or 5 years (depending on the woman’s
age); and the proportion of persons aged 60–69 screened
for bowel cancer in the prior 30months (see
Supplementary Appendix). The available practice’s popu-
lation characteristics included those related to (a) the
burden of chronic conditions (proxies: proportion of
patients with long-standing health conditions, and the pro-
portion with caring responsibilities other than for under-
age children), (b) deprivation (proxies: index of multiple
deprivation (IMD), proportion of unemployed patients),
Figure 1. Study design for individual-level data.
Main analysis, example for women last known to be alive (¼reference date) on 31 December 2010. ADHE: the six-year period to determine
participation in cervical screening. BDHF: the four-year period to determine participation in breast screening. CDHG: the three-year period
to determine participation in bowel screening.
Additional analysis, to determine participation in breast and cervical screening before age 54 years. LIKN: the six-year period to determine
participation in cervical screening. MJKN: the four-year period to determine participation in breast screening.
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(c) health behaviours (proxy: proportion of patients smok-
ing), and (d) satisfaction with the general practice (proxy:
proportion of patients that would recommend the general
practice to others). IMD is a standard English composite
measure of deprivation taking into account employment
rate, income, education, health, crime, housing, and living
environment within a postcode.33 None of the definitions
of the screening and descriptive indicators could be manip-
ulated, e.g. broken down into narrower age and sex
groups, by users.
We defined three groups of practices: those with the
same or higher, those with a lower screening coverage
than the national average for all three programmes con-
currently (“high-coverage practices” and “low-coverage
practices”, respectively), and those where the coverage
was higher in some but lower in other programmes
(“mixed-coverage practices”). We implicitly assumed that
the high-coverage practices were more likely to include
women who participated in all three programmes concur-
rently, although we could not verify this independently.
We categorized practice characteristics into approximately
tertiles (in as much as possible after rounding on the
second decimal). We used logistic regression to calculate
odds ratios (OR) for high-coverage or mixed-coverage sep-
arately vs. low-coverage, depending on practice character-
istics. For each practice characteristic, the OR was
adjusted for all other practice characteristics under study.
Analyses were undertaken with RStudio, version
1.1.463 (R version 3.5.2).34
Results
Individual-level data
Of the 3060 women, most (2989, NEP; 98%) had at least
one screening participation record ever, and 71 (NNP; 2%)
were never screened in any of the programmes. In the last
screening round before the reference date, 2525 (Nbreast;
83%) women were screened for breast, 1908 (Ncervix;
62%) for cervical, and 1635 (Nbowel; 53%) for bowel
cancer, which is consistent with the proportions reported
in the official statistics for England (78%, 58–59%, and
57–59%, respectively, as reported above).
With completely random concurrent participation, 882
(29%) women would have participated in all three pro-
grammes, and 147 (5%) in none. The observed data
showed that 1086 (35%) were screened for all three can-
cers, and 306 (10%) for none (Table 1). Hence, concurrent
(non-) participation was not a random occurrence
(p< 0.001 in both cases). Furthermore, 1142 (37%)
women participated in two, and 526 (17%) in a single
screening programme (Figure 2). Women who participated
in a given screening programme were more likely to par-
ticipate in both other recommended programmes than
were women who did not participate in that programme
(Table 2). Those who participated in that programme were
less likely not to undergo screening in the other two pro-
grammes. For example, 43% of those who participated in
Table 1. Individual-level data for 3060 English women:
Concurrent participation in the three screening programmes,
by screening programme.
Number of
screening
programmes
attended
Participated in screening for
Breast
cancer
Cervical
cancer
Bowel
cancer N (%)
3 Yes Yes Yes 1086 (35)
2 Yes Yes No 639 (21)
Yes No Yes 445 (15)
No Yes Yes 58 (2)
1 Yes No No 355 (12)
No Yes No 125 (4)
No No Yes 46 (2)
0 No No No 306 (10)
Total – – – 3060 (100)
Figure 2. Participation in individual screening programmes, and concurrent participation in all three programmes in the last invitation round.
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breast screening also participated in both cervical and
bowel screening, while only 11% did so among those
who did not participate in breast screening. While 14%
of those who participated in breast screening obtained
no other cancer screening, 57% of those who did not par-
ticipate in breast screening obtained no other cancer
screening either. Nevertheless, only about half of partici-
pants in a given programme also participated in both other
programmes (43%, 57%, and 66% of breast, cervical, and
bowel screening participants, respectively).
These results were reasonably robust for the cessation
of screening due to hysterectomy and the gradual roll-out
of bowel screening (not tabulated). Firstly, at age 60–65,
1725 (56%) women participated in both cervical and
breast screening programmes, 983 (32%) participated in
one, and 352 (12%) participated in none (Table 1).
Before age 54, the overall picture remained similar: 1933
(63%) women participated in both, 874 (29%) in one, and
253 (8%) in neither of the two programmes. Secondly,
among the 2391 women with an invitation to bowel screen-
ing sent in the year preceding their reference date or ear-
lier, 988 (41%) attended all three screening programmes,
823 (34%) attended two, 361 (15%) attended one, and 219
(9%) attended none, compared with 35%, 37%, 17%, and
10%, respectively, in the main analysis that included all
3060 women (Table 1).
General practice data
Of the 7014 practices, 3354 (48%) attained a breast screen-
ing coverage of at least 72.1%, 4075 (58%) attained a cer-
vical screening coverage of at least 71.7%, and 3234 (46%)
attained a bowel screening coverage of at least 57.3% (all
three thresholds were national averages in 2017/18). In the
most deprived areas (highest IMD tertile), only 5% of the
practices attained above-average participation in all three
screening programmes concurrently, whereas 62% of the
practices attained below-average participation. An oppo-
site pattern was seen among the practices with the lowest
levels of deprivation, where 64% had consistently better
screening coverage rates than the national average, and
only 8% of the practices were underperforming.
The ORs for deprivation and screening participation in
the three programmes combined were highly statistically
significant (Table 3). Similarly, practices with a higher pro-
portion of unemployed patients and those with a higher
proportion of smokers were less likely to attain a high
coverage in all three screening programmes. Higher cover-
age was more frequent among practices with a higher pro-
portion of carers, of individuals with long-term health
conditions, and those with a high level of patient satisfac-
tion with the practice itself. The patterns resembled a
dose–response relationship, with the values for screening
participation in the middle tertile of practice characteris-
tics falling between those for the lowest and the highest
tertiles, and those for the mixed-coverage practices
falling between those for low-coverage and high-
coverage practices.
Discussion
To decrease the chances of dying from specific cancers, it is
important for the population to attend all screening pro-
grammes as recommended. Virtually all women in our
English dataset (98%) had ever undergone at least one
cancer screening test. About four out of five women were
up-to-date with breast, two out of three with cervical, and
just over one in two with bowel screening. Although not
entirely surprising given this variation in programme-
specific participation, it is nevertheless disconcerting that
only about one in three women were up-to-date with all
their recommended cancer screens, and one in ten
remained completely unscreened in the last round. While
we observed the same patterns as elsewhere, in that
participants in one programme were also substantially
more likely to participate in another screening pro-
gramme,20,21,23,24,26 only half of women who participated
at least once did in fact participate in all other recom-
mended screening. Taken together, this means that the
targeted population is less well protected from all three
cancers simultaneously than the participation rates
from the individual screening programmes could suggest,
although nine out of ten are protected against dying
Table 2. Individual-level data for 3060 English women: Concurrent participation in the three screening programmes, by whether the woman
participated in a specific programme.
Participated in additional screening programmes
Two One None
Participated in screening for: N (%) RP (95% CI) N (%) RP (95% CI) N (%) RP (95% CI)
Breast cancer: no (N¼ 535) 58 (11) 1 (ref) 171 (32) 1 (ref) 306 (57) 1 (ref)
Breast cancer: yes (N¼ 2525) 1086 (43) 3.97 (3.10–5.08) 1084 (43) 1.34 (1.18–1.53) 355 (14) 0.25 (0.22–0.28)
Cervical cancer: no (N¼ 1152) 445 (39) 1 (ref) 401 (35) 1 (ref) 306 (27) 1 (ref)
Cervical cancer: yes (N¼ 1908) 1086 (57) 1.47 (1.36–1.60) 697 (37) 1.05 (0.95–1.16) 125 (7) 0.25 (0.20–0.30)
Bowel cancer: no (N¼ 1425) 639 (45) 1 (ref) 480 (34) 1 (ref) 306 (21) 1 (ref)
Bowel cancer: yes (N¼ 1635) 1086 (66) 1.48 (1.39–1.58) 503 (31) 0.91 (0.82–1.01) 46 (3) 0.13 (0.10–0.18)
CI: confidence interval; RP: relative proportion.
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from specific cancers at least through one of
the programmes.
Evaluations of cancer screening are typically undertak-
en for individual programmes. It may, however, be useful
also to consider analysing the recommended combination
of multiple programmes as a single package, recognizing
that all cancer screening has a shared goal in avoiding
premature mortality and reducing treatment complica-
tions. Also, while the individuals may prefer particular
screening tests over others,14 they often do not have a
nuanced perception of the differences between cancers.35,36
Studies such as ours provide some of the first indications
of how the accumulation of multiple (evidence-based)
screening programmes unfolds in practice. Our data clear-
ly show that, for most women, screening does not appear
to be a consistent habit, even when offered for free.
The detected deviation from the assumption of random-
ness would suggest that those who participate in all rec-
ommended screening may share certain traits, as do those
who do not participate. Further exploration of these
associations between multiple programmes could lead to
a better understanding of the complexities in screening
evaluation, such as self-selection. The latter can exaggerate
the estimated benefit of screening on mortality.26,37,38
Participation is frequently thought to be more common
among healthier individuals such as non-smokers, who
would have better health outcomes even in the absence
of screening.20,26,39–43 This was also suggested by the
English general practice data. Nevertheless, the associa-
tions between population characteristics are probably
more complex than they appear on the surface. For exam-
ple, smokers are probably overrepresented among those
who suffer from certain chronic conditions, and yet a
high burden of chronic conditions within a general prac-
tice was associated with higher screening coverage rates in
all three programmes combined. Being confronted with
someone else’s disease and/or frailty as a carer also
seemed to be positively associated with participation. It
is possible that these patterns, rather than merely showing
a direct association between patients’ health and cancer
screening, also reflect the context of the frequency of con-
tact with the general practice or health care in general,
and/or the satisfaction therewith. Various other practice
characteristics, such as deprivation and unemployment,
also appeared to have a strong association with participa-
tion. While remaining mindful that these are ecological
data, it appears that the wider social and economic context
may play a role in motivating the population to undergo
all recommended cancer screening.
These data still point to a role of personal character-
istics that have been traditionally associated with (non-)
participation in a single type of cancer screening,10,14,15 but
the nature of this association requires further elucidation.
While these factors may contribute to an individual opting
for a certain type of screening, there seems to be an addi-
tional driver whereby the same person may find additional
screening tests unacceptable, unnecessary, or simply not
a priority. Future research may also need to investigate
how the differences between the screening tests14,25 or fac-
tors related to an individual’s vulnerability44,45 affect par-
ticipation in more than one screening programme. Finally,
alternative venues for screening provision, for example
one-stop screening clinics, could be considered, as well as
alternative ways of approaching those women who obtain
some but not all recommended screening.
Although the controls were age-matched to their cases,
they were otherwise randomly selected from the invited
population. Information on screening participation was
obtained from national registers, minimizing the risk of
selective recall, which may have been present in previous
studies that tended to rely on self-reported data.20–26 In
our study, the participation rates in each programme
were similar to those reported in the official national sta-
tistics for all three programmes, suggesting that our data
are representative for the invited population. The propor-
tion who undergo all screening may these days be slightly
lower, as screening participation has decreased by about
three percentage points in each programme since
2010.27,28,46 Additional analyses showed that our conclu-
sions were robust to the gradual roll-out of bowel screen-
ing and to cessation of screening due to hysterectomy, for
which additional data were not available. Finally, our
analysis would be further improved by having access to
each woman’s sociodemographic background. Instead,
we used general practice data from the same source pop-
ulation, although these ecological correlations should be
interpreted cautiously.
Conclusion
Despite satisfactory participation rates in the individual
cancer screening programmes, only about a third of
English women undergo all recommended cancer screen-
ing. Future studies should investigate the reasons why
most of those who participate in some screening do not
participate in all recommended screening, to inform poli-
cies which will contribute to fewer deaths from cancer.
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